GH Research price target lowered to $39 from $50 at JMP Securities

JMP Securities analyst Jason Butler lowered the firm’s price target on GH Research to $39 from $50 and keeps an Outperform rating on the shares following the Q4 earnings report. GH Research reported Q4 financial results and provided a corporate update, reiterating that the Phase 2b trial in treatment resistant depression remains on track to complete in 3Q24 with results in 4Q24, and that it has initiated preclinical studies requested by the Food and Drug Administration to address the clinical hold, the analyst tells investors in a research note.